Aether Biomedical
Aether Biomedical is a Polish medical-device company that develops the Zeus multi-articulating bionic hand and connected prosthetic rehabilitation technology for upper-limb amputees.
- CEO / Founder
- Dhruv Agrawal
- Team Size
- 51-200
- Stage
- Growth Stage
- Total Funding
- $10.3M
- Latest Round
- Series A
- Key Investors
- J2 Ventures; Story Ventures; Chiratae Ventures; Sunfish Partners
Technology & Products
Key Products
Zeus Hand V2 and V1 multi-articulating bionic hands (sizes S and M); Aether MyoSense EMG electrode system; Aether digital platform (ADP) for device configuration and monitoring; integrated battery system with USB-C charging; EQD quick-disconnect and Flex wrist options.
Technological Advantage
Advanced bio-signal processing (EMG via Aether MyoSense) combined with IoT, machine learning and deep learning for intuitive control; additive manufacturing (Carbon Digital Light Synthesis with RPU 130 resin) enables complex internal cavities, thin ~1mm walls and rapid design iteration, supporting modular field-repairable construction and scalable production.
Differentiation
Value Proposition
Delivers an affordable, durable, multi-articulating bionic hand with advanced bio-signal processing and a connected clinical platform, aiming to make advanced bionics accessible to upper-limb amputees worldwide.
How They Differentiate
Focuses on affordability and accessibility with a modular, locally repairable design (parts shipped directly to clinicians) and connected cloud-based patient-provider communication, versus competitors' higher-cost, manufacturer-service-return models. Claims 30-40% stronger grip than other market options.
Market & Competition
Target Customers
Upper-limb amputees and the orthotic/prosthetic (O&P) clinics and clinicians who fit and service them; distributors across Europe, the US, India and Ukraine.
Industry Verticals
Medical devices; prosthetics and orthotics; rehabilitation; assistive technology
Competitors
Open Bionics; Össur; Ottobock; Esper Bionics
Growth & Milestones
Growth Metrics
Grew approximately 100% year over year; expects more than 1,000 patients fitted with a Zeus hand in 2026; distributed 250+ Zeus hands in 2023; scaled Zeus production from ~5-10 to 100+ units monthly via Carbon DLS.
Major Milestones
2018: Established Poland HQ and received Poland Prize grant. 2019: First VC round plus RobotUnion and NCBR Fast Track grants. 2020: Launched Zeus V1 as CE-marked device in Poland and India. 2021: Expanded across Europe; established US HQ in Chicago. 2022: Launched Zeus V1 in US with PDAC approval under L6880. 2023: Closed $5.8M Series A. 2024: Partnered with Superhumans Center to deliver bionic limbs in Ukraine. 2025: Zeus S release. 2026: Zeus M release and Aether MyoSense; ranked #50 in Sifted 100 DACH & CEE.
Notable Customers
Orthotic and prosthetic (O&P) care providers in the US; Inovamed (Poland); Superhumans Center (Ukraine); ODF Foundation (Ukraine veterans); Medicare and most commercial US payers cover the Zeus hand.